BANB:SIXBachem Holding AG Class B Analysis
Data as of 2026-03-15 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Bachem Holding AG trades around CHF 61, sitting just above its 20‑day SMA (≈59.5) but below the 50‑day SMA (≈63.9), indicating a modest short‑term upside. The RSI is near the midpoint at 51 and the MACD histogram is positive, giving a bullish signal despite a neutral overall trend. However, the current price exceeds the DCF‑derived fair value of roughly CHF 49.6, suggesting the market is pricing in aggressive growth expectations. The company posted a 30% year‑over‑year revenue surge and maintains a gross margin of about 31%, yet free cash flow is negative and debt‑to‑equity stands at a high 4.5, raising concerns about cash sustainability. Dividend yield is modest at 0.74% with a payout ratio near 48%, and the beta of 0.5 combined with a 30‑day volatility of 60% points to low systematic risk but high price swings. Volume is increasing, and the stock sits between support at CHF 53.95 and resistance at CHF 67.95, while the Fear & Greed Index reads 73 (Greed), implying bullish market sentiment.
Market Outlook
Short Term
< 1 yearKey Factors
- Price near short‑term support with bullish MACD histogram
- Neutral RSI and increasing volume
- Overvaluation relative to DCF fair value
Medium Term
1–3 yearsKey Factors
- Strong revenue growth but high debt‑to‑equity
- Negative free cash flow limiting reinvestment
- Moderate sector and regulatory exposure
Long Term
> 3 yearsKey Factors
- Sustained growth potential in peptide and oligonucleotide markets
- Dividend sustainability concerns
- Elevated valuation may compress future returns
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.